PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX for Prevention of Abdominal Colorectal Surgical Site Infections
| PYPD Stock | USD 2.79 0.25 9.84% |
About 54% of PolyPid's shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding PolyPid suggests that some traders are interested. The current market sentiment, together with PolyPid's historical and current headlines, can help investors time the market. In addition, many technical investors use PolyPid stock news signals to limit their universe of possible portfolio assets.
Company Recently Reached Agreement with FDA on Design of Trial Top-line Results Expected in Mid-2024 PETACH TIKVA, Israel, June 22, 2023 PolyPid Ltd. , a late-stage biopharma company aiming to improve surgical outcomes, today announced that the first patient has been recruited and is scheduled for surgery in its revised SHIELD II Phase 3 trial evaluating D-PLEX100 for the prevention of abdominal colorectal surgical site infections S
Read at finance.yahoo.com
 |
PolyPid Fundamental Analysis
We analyze PolyPid's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PolyPid using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PolyPid based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
PolyPid is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
PolyPid Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with PolyPid stock to make a market-neutral strategy. Peer analysis of PolyPid could also be used in its relative valuation, which is a method of valuing PolyPid by comparing valuation metrics with similar companies.
Peers
PolyPid Related Equities
| INAB | In8bio | 7.14 | ||||
| ARMP | Armata Pharmaceuticals | 4.33 | ||||
| PYXS | Pyxis Oncology | 4.17 | ||||
| ELEV | Elevation Oncology | 3.33 | ||||
| ANIX | Anixa Biosciences | 2.76 | ||||
| ZURA | Zura Bio | 2.00 | ||||
| CUE | Cue Biopharma | 1.59 | ||||
| KPRX | Kiora Pharmaceuticals | 1.35 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.78 | ||||
| INMB | INmune Bio | 3.79 | ||||
| VRAX | Virax Biolabs | 7.62 | ||||
| REVB | Revelation Biosciences | 14.98 |
Complementary Tools for PolyPid Stock analysis
When running PolyPid's price analysis, check to measure PolyPid's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPid is operating at the current time. Most of PolyPid's value examination focuses on studying past and present price action to predict the probability of PolyPid's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPid's price. Additionally, you may evaluate how the addition of PolyPid to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Transaction History View history of all your transactions and understand their impact on performance |